European Pharmaceutical Review

MARCH 9, 2023

1 These substances “are pharmacologically and biologically active at low doses,” Dr Kishore Hotha, Global Head of Analytical Research & Development at Veranova, explained. ” Highly potent APIs are pharmacologically and biologically active compounds at low doses. What training is required for employees to handle HPAPIs safely?

Safety 92

Safety Pharmacology Training Manufacturing 92

pharmaphorum

JANUARY 17, 2023

Angion chalked up a series of trial failures for its hepatocyte growth factor (HGF) mimetic ANG-3777 over the last couple of years, and turned its attention to tyrosine kinase receptor inhibitor ANG-3070 in kidney diseases and fibrotic disorders, before abandoning the drug due to safety concerns in the middle of 2022. Darrell Irvine.

Pharmacology 62

Pharmacology Engineering Consulting Leads 62

European Pharmaceutical Review

DECEMBER 11, 2023

Based on learnings from ASOs and siRNAs they also leverage unique engineering and drug delivery techniques that enable them to target a broader set of cell types, including many that have been previously untreatable with RNA therapeutics. 8 In contrast, AOCs are not limited to RNA degradation or splicing modification alone.

Pharmacology 85

Pharmacology Safety Engineering Medical 85

European Pharmaceutical Review

SEPTEMBER 22, 2023

7 It is currently being evaluated in a Phase Ib/IIa clinical study, demonstrating to date a good safety profile. While favourable safety has been reported up to the Phase II, the relevance of targeting the C-terminal portion of Abeta still needs to be confirmed.

Food and Drug Administration 79

Food and Drug Administration Safety Patients Leads 79